Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus

Go back to Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus
TANDEM DIABETES (NASDAQ: TNDM) Delayed: 14.41 +0.07 (0.49%)
Previous Close $14.34    52 Week High $12.48 
Open $14.17    52 Week Low $1.60 
Day High $14.49    P/E N/A 
Day Low $13.95    EPS $-6.33 
Volume 3,498,149